Investigating a new treatment for men with advanced prostate cancer resistant to standard therapies
Official title: A Phase 2, Single-Arm Study of the CXCR1/2 Inhibitor SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (mCRPC)
Funded at Syntrix Biosystems, INC. · NIH-10884438 · Data updated 2026-11-12
This study is looking for men with advanced prostate cancer who haven't had success with common treatments to see if a new drug called SX-682, when combined with enzalutamide, can help improve their treatment results.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Syntrix Biosystems, INC. NIH-funded |
| Lab location | 1 site (Auburn, United States) |
| Project start | July 7, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $745,050 |
| NIH project number | 5R44CA278187-02 |
| Project ID | NIH-10884438 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have previously shown resistance to abiraterone.
✕Less likely to help
Patients who have not been diagnosed with metastatic castration-resistant prostate cancer or those who have not previously received abiraterone may not benefit from this research.
What this research studies
This research focuses on men with metastatic castration-resistant prostate cancer (mCRPC) who have not responded to standard treatments like abiraterone and enzalutamide. The study evaluates the combination of a new drug, SX-682, which inhibits specific chemokine receptors, alongside enzalutamide to see if it can improve treatment outcomes. By targeting the tumor microenvironment and overcoming resistance mechanisms, the research aims to provide a more effective therapy for these patients. Participants will receive the treatment and be monitored for their response over the course of the study.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that improves survival and quality of life for men with advanced prostate cancer.
How similar studies have gone: Other research has shown promise in targeting chemokine receptors in cancer treatment, indicating that this approach may be effective.
Where this research is happening
-
Syntrix Biosystems, INC.
Auburn, United States Active
Researchers
- Principal investigator: Schuler, Aaron D — Syntrix Biosystems, INC.
- Study coordinator: Schuler, Aaron D
Related research
Other NIH-funded projects on the same topics.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
A newly discovered heavily methylated form of advanced prostate cancer
Researchers are looking at a newly found heavily methylated type of advanced prostate cancer to find markers and possible weak points for treatment in men with metastatic castration‑resistant prostate cancer.
-
A new treatment for advanced prostate cancer that has stopped responding to abiraterone.
This research is testing a new combination of medicines, SX-682 and enzalutamide, for men whose advanced prostate cancer has become resistant to abiraterone.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.